# Testing a novel, self-contained chest drainage system (THOPAZ+) for post-operative cardiac drainage

Submission date	Recruitment status	<ul><li>Prospectively registered</li></ul>
29/05/2019	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
07/06/2019	Completed	Results
Last Edited	Condition category	Individual participant data
27/08/2019	Surgery	Record updated in last year

## Plain English summary of protocol

Background and study aims

Most cardiac procedures still require the use of cardiopulmonary bypass (CPB) and a sternotomy. One of the complications after such procedures is bleeding, since patients have to be fully anti-coagulated during CPB and therefore require post-operative chest drainage.

Aim: A new, self-contained, electronic, continuous pump-driven chest drainage system is compared for the first time in an RCT to a traditional wall-suction system in cardiac surgery.

#### Who can participate?

Adult elective cardiac patients undergoing CABG and/or valve surgery.

#### What does the study involve?

Patients undergoing cardiac surgery require post-operative chest-drainage in order to evacuate blood and clot formation. This is achieved with one or several chest-tubes which are hooked to a conventional canister system drained by vacuum. The aim of our study was to assess a new, self-contained, battery-operated, digital drainage system (THOPAZ+) and to compare it to a conventional system. Our prospective, randomized clinical trial included 120 patients undergoing elective routine cardiac surgery. They were randomized between the group with conventional and the group with THOPAZ+ drainage.

What are the possible benefits and risks of participating?

The benefits of the new system are a continuous drainage from the operating room until the chest-tube removal, the possibility to mobilize the patient and the presence of alarms on the THOPAZ+ system and a shorter drainage duration which may have a positive impact on the outcome of the patient.

Where is the study run from?

Department of Cardiac Surgery, University Hospital, Verona, Italy.

When is the study starting and how long is it expected to run for? September 2015 to June 2016

Who is funding the study? Medela AG, Switzerland

Who is the main contact?
Dr Luca Barozzi,
luca.barozzi@ospedaleuniverona.it

# Contact information

## Type(s)

Scientific

#### Contact name

Dr Luca Barozzi

#### **ORCID ID**

https://orcid.org/0000-0001-5297-0058

#### Contact details

Cardiac Surgery
University Hospital of Verona
Piazzale le Stefani 1
Verona
Italy
37126
0039 347 2739 436
luca.barozzi@ospedaleuniverona.it

# Additional identifiers

# Clinical Trials Information System (CTIS)

Nil known

# ClinicalTrials.gov (NCT)

Nil known

#### Protocol serial number

584CESC

# Study information

#### Scientific Title

Randomized controlled trial of a novel, self-contained chest drainage system in cardiac surgery

## Acronym

ThopCard2

# **Study objectives**

Improvement of chest drainage: we have investigated a new chest drainage system THOPAZ+ (Medela AG, Switzerland) to improve and simplify the management of chest drainage after cardiac surgical procedures and which gives the patient a small, mobile, user-friendly, continuous suction from the operating table to the ICU/ward.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Approved 28/07/2015, Ethics Committee of the University of Verona (Borgo Trento, P. le A. Stefani, 1-37126 Verona, Italy; 045 8123236; comitatoetico.veronarovigo@ospedaleuniverona. it), ref: 584CESC.

#### Study design

Interventional single centre study

#### Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Cardiac surgery

#### **Interventions**

This study compared the conventional chest drainage system (Argyle Aqua-Seal, Covidien, USA) with the new THOPAZ+ digital self-contained system from the end of cardiac surgery until the chest tube removal.

Randomization: Patients were allocated to either the usual suction system or the Thopaz+ pump using block randomization, with blocks of 4 or 6 (block size is also random). Group allocation was put in sealed envelopes, which were opened after surgery, just before the OR nurse opened the tubing system. Thus, the surgical team was blinded to the suction system during the surgery.

All the data were collected prospectively during the study by two surgical residents and supervised by Dr. Luca Barozzi.

#### Intervention Type

Device

#### Phase

Not Applicable

#### Primary outcome(s)

Adequecy of chest drainage with THOPAZ+ measured on the digital read-out of the THOPAZ+ (in ml of drainage fluid) at the following time points: end of OR, before and after transport to ICU, on ICU (hourly), POD1, and at chest-tube removal.

# Key secondary outcome(s))

Patient safety and Satisfaction Assessment of the hospital personnel.

- 1. The patient safety was part of the routine ICU care of the patient and special attention was given to the functioning of the THOPAZ+ chest drainage system, e.g. fluid collection, air leak.
- 2. The satisfaction assessment of the hospital personnel was performed with a short, internet-based form was filled by the users according to their specialty, e.g. cardiac surgeons, anesthetists, nurses to measure the following characteristics of the device on a visual analog scale (from 0 to 10).
- -Ease of use
- -No/reduced milking
- -Mobility of patients
- -Noise reduction
- -Gain of time
- -Security for patients
- -How useful were the alarms?

#### Completion date

20/06/2016

# **Eligibility**

#### Key inclusion criteria

- 1. Adult aged 18 80 years
- 2. Scheduled to undergo elective, first-time: CABG, valve surgeries and combinations with cardio-pulmonary bypass (CPB)

# Participant type(s)

**Patient** 

#### Healthy volunteers allowed

No

#### Age group

Adult

#### Lower age limit

18 years

#### Sex

All

## Key exclusion criteria

- 1. Unstable angina
- 2. Emergency procedures
- 3. Off-pump surgery
- 4. Re-operation
- 5. Anti-coagulation or anti-platelet therapy (except aspirin cardio) until surgery

#### Date of first enrolment

17/09/2015

# Date of final enrolment 14/06/2016

# Locations

Countries of recruitment Italy

Study participating centre
Department of Cardiac Surgery
University Hospital
Piazzale le Stefani 1
Verona
Italy
37126

# Sponsor information

#### Organisation

Medela AG

#### **ROR**

https://ror.org/02cedh792

# Funder(s)

Funder type

Industry

#### **Funder Name**

Medela AG

# **Results and Publications**

# Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are available from the corresponding author on special request from Dr. Luca Barozzi, luca.barozzi@ospedaleuniverona. it with the following access criteria: detailed description for which purpose the anonymized data, or part of the data, will be used and only after having received permission from the Ethical Commission of the University of Verona.

# IPD sharing plan summary

Data sharing statement to be made available at a later date

# **Study outputs**

Output type Details Date created Date added Peer reviewed? Patient-facing?

Participant information sheet
Participant information sheet
11/11/2025 No Yes